Functional Characterization of the β-Adrenergic Receptor Subtypes Expressed by CA1 Pyramidal Cells in the Rat Hippocampus

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 314; no. 2; p. 561
• Main Authors: Kristin L. Hillman, Van A. Doze, James E. Porter
• Format: Journal Article
• Language: English
• Published: American Society for Pharmacology and Experimental Therapeutics 01.08.2005
• ISSN: 0022-3565; 1521-0103
• DOI: 10.1124/jpet.105.084947

Recent studies have demonstrated that activation of the β-adrenergic receptor (AR) using the selective β-AR agonist isoproterenol (ISO) facilitates pyramidal cell long-term potentiation in the cornu ammonis 1 (CA1) region of the rat hippocampus. We have previously analyzed β-AR genomic expression patterns of 17 CA1 pyramidal cells using single cell reverse transcription-polymerase chain reaction, demonstrating that all samples expressed the β2-AR transcript, with four of the 17 cells additionally expressing mRNA for the β1-AR subtype. However, it has not been determined which β-AR subtypes are functionally expressed in CA1 for these same pyramidal neurons. Using cell-attached recordings, we tested the ability of ISO to increase pyramidal cell action potential (AP) frequency in the presence of subtype-selective β-AR antagonists. ICI-118,551 [(±)-1-[2,3-(dihydro-7-methyl-1 H -inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-butanol] and butoxamine [α-[1-( t -butylamino)ethyl]-2,5-dimethoxybenzyl alcohol) hydrochloride], agents that selectively block the β2-AR, produced significant parallel rightward shifts in the concentration-response curves for ISO. From these curves, apparent equilibrium dissociation constant ( K b ) values of 0.3 nM for ICI-118,551 and 355 nM for butoxamine were calculated using Schild regression analysis. Conversely, effective concentrations of the selective β1-AR antagonists CGP 20712A [(±)-2-hydroxy-5-[2-([2-hydroxy-3-(4-[1-methyl-4-(trifluoromethyl)-1 H -imidazol-2-yl]phenoxy)propyl]amino)ethoxy]-benzamide methanesulfonate] and atenolol [4-[2′-hydroxy-3′-(isopropyl-amino)propoxy]phenylacetamide] did not significantly affect the pyramidal cell response to ISO. However, at higher concentrations, atenolol significantly decreased the potency for ISO-mediated AP frequencies. From these curves, an apparent atenolol K b value of 3162 nM was calculated. This pharmacological profile for subtype-selective β-AR antagonists indicates that β2-AR activation is mediating the increased AP frequency. Knowledge of functional AR expression in CA1 pyramidal neurons will aid future long-term potentiation studies by allowing selective manipulation of specific β-AR subtypes.